Asia Pacific
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Japan Eyes Cutting Reimbursement For COVID-19 Drugs
Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.

FDA’s Califf Speaks Of Tailoring Trials For CMS Evidence Amid Spotlight On Alzheimer’s Drugs
FDA Commissioner Robert Califf spoke of the need for a better hand-off to CMS, including tailoring trials to generate evidence relevant for Medicare coverage. He also weighed in on the possibility of accelerated approval for chronic disease drugs, among other topics.

Japan Readies One-Off Price Cuts For Big Sellers
Japanese regulatory authorities have announced a set of additional reimbursement price cuts for selected products in August, under which Novartis’s heart failure drug Entresto will see its price slashed by 15%. A batch of other newly approved drugs has also been priced.

China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.

Australian Regulator Warns Of Delays To GMP Clearance Processes
Drug sponsors have been told to continue applying for extensions to good manufacturing practice clearances for overseas manufacturing sites as long as they meet the criteria for extension and apply in good time.

India Clinical Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.

Japan Finally Approves Mifepristone To Public Support
Japan has approved abortion drug mifepristone but will limit its use to clinics with authorized physicians, with strict nationwide monitoring of sales. The majority of more than 10,000 public comments around the approval were in support of the new option for women.

Companies Vigilant As China Expands Wide-Ranging Anti-Espionage Legislation
The recent arrest of a local Japanese employee of Astellas triggered alarms for pharma firms operating in China, while a newly-expanded and wide-ranging anti-espionage law means that sponsors must pay careful attention to overseas data transfers, especially related to clinical trials, business intelligence and due diligence, as well as other activities.

Pakistan Consults On Content Of Patient Information Leaflets
Pakistan’s medicines regulator is inviting stakeholder feedback on its approach to presenting information in patient information leaflets to support the safe and effective use of medicines.

IP Divisions In Indian Courts: Will Pharma See Expediated Adjudication?
A second court in India establishes an intellectual property division to consider IPR matters and notifies rules following the dissolution of the Intellectual Property Appellate Board in 2021. Legal experts outline what that may mean for the efficiency and quality of IPR adjudications.

Global Pharma Guidance Tracker – April 2023
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Korea’s Clinical Trial Landscape In 2022: Approvals Fall To Pre-COVID Levels
The Pink Sheet takes an infographic look at South Korea's clinical trial trends in 2022 to illustrate how the country's biopharma R&D is developing and how activities are recovering in the post-pandemic situation. One key takeaway is that approvals for trial starts have fallen back to pre-COVID levels, suggesting a falling off of activity related to drugs and vaccines for the virus.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.